Pilot Study to Measure Uric Acid in Traumatized Patients: Determinants and Prognostic Association
Study Overview
Status
Status
Conditions
Conditions
Study Type
Study Type
Enrollment (Anticipated)
Enrollment
Contacts and Locations
Study Locations
-
-
Quebec
-
Montreal, Quebec, Canada, h4j1c5
- Hôpital du Sacré-Cœur de Montréal
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
- Direct admission to trauma center
- ≤ 3h after trauma
- ISS ≥ 16
- Received at least 1L of fluid at ER entrance
Exclusion Criteria:
- Isolated head injury
- Isolated spine injury
- Chemotherapy within the last month
- Hematologic disease
- Chronic hemodialysis
- Uricase treatment within the last week
- Expected death within 48h
Study Plan
How is the study designed?
Design Details
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Feasibility of serial plasmatic uric acid sampling after trauma
Time Frame: 7 days
|
Number of measures collected/number of measures planned
|
7 days
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Impact of resuscitation on uric acid measures
Time Frame: 24 to 48 hours
|
Impact of fluid administration (amount in mL) on the changes of subsequent uric acid blood level
|
24 to 48 hours
|
|
Clinical predictors of the first blood uric acid (μmol/L) level measured
Time Frame: 12 hours
|
Impact of patient's characteristics and physiological variables on the first measured blood uric acid. Characteristics will include: age (years), gender, Injury severity score, presence of acute renal impairment. Physiological variables will include: lower systolic blood pressure, base deficit, lactate level |
12 hours
|
Collaborators and Investigators
Sponsor
Sponsor
Collaborators
Collaborators
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Anticipated)
Primary Completion
Study Completion (Anticipated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- 263425
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.